PMID- 18005064
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20131121
IS  - 0953-816X (Print)
IS  - 0953-816X (Linking)
VI  - 26
IP  - 11
DP  - 2007 Dec
TI  - MDMA self-administration in rats: acquisition, progressive ratio responding and 
      serotonin transporter binding.
PG  - 3229-36
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) self-administration has been shown in 
      animals with extensive drug histories, but only a small number of studies have 
      examined high rates of responding maintained by MDMA in previously drug-naive 
      animals. In the present study, influence of dose (0.25 or 1.0 mg/kg/infusion) on 
      the acquisition of MDMA self-administration was measured during daily 6-h 
      sessions. Dose-effect data were obtained for MDMA (0.25-1.0 mg/kg/infusion) 
      self-administration under a progressive ratio (PR) schedule of reinforcement. The 
      effect of experimenter- or self-administered MDMA on [3H] paroxetine binding in 
      several brain regions was measured. Acquisition of MDMA self-administration was 
      highly variable and not different for 0.25 or 1.0 mg/kg/infusion progressed with 
      approximately 60% of the rats acquiring reliable self-administration during the 
      15-day test period. The percentage of rats that acquired MDMA self-administration 
      was lower than the percentage of rats that acquired cocaine (0.5 mg/kg/infusion) 
      self-administration, and cocaine self-administration was acquired with a shorter 
      latency. Responding maintained by MDMA was dose dependent, and breakpoints under 
      a PR schedule increased with dose. Radioligand binding and autoradiography 
      demonstrated lower densities of serotonin transporter sites (SERT) in MDMA 
      self-administering rats as compared with controls across brain regions. The 
      reduction in SERT densities was comparable in magnitude to rats treated with 
      experimenter-administered doses of MDMA. These data support the idea that MDMA is 
      a drug with high abuse liability, and long-term self-administration may lead to 
      long-lasting deficits in serotonin neurotransmission.
FAU - Schenk, Susan
AU  - Schenk S
AD  - Victoria University of Wellington, School of Psychology, Wellington, New Zealand. 
      Susan.Schenk@vuw.ac.nz
FAU - Hely, Lincoln
AU  - Hely L
FAU - Lake, Barbara
AU  - Lake B
FAU - Daniela, Evangelene
AU  - Daniela E
FAU - Gittings, David
AU  - Gittings D
FAU - Mash, Deborah C
AU  - Mash DC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071114
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Dopamine Uptake Inhibitors)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 10028-17-8 (Tritium)
RN  - 41VRH5220H (Paroxetine)
RN  - I5Y540LHVR (Cocaine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Autoradiography/methods
MH  - Behavior, Animal/drug effects
MH  - Cocaine/pharmacology
MH  - Conditioning, Operant/*drug effects
MH  - Dopamine Uptake Inhibitors/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage
MH  - Paroxetine/metabolism
MH  - Protein Binding/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Self Administration/methods
MH  - Serotonin Agents/*administration & dosage
MH  - Serotonin Plasma Membrane Transport Proteins/*metabolism
MH  - Tritium/metabolism
EDAT- 2007/11/17 09:00
MHDA- 2008/02/26 09:00
CRDT- 2007/11/17 09:00
PHST- 2007/11/17 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2007/11/17 09:00 [entrez]
AID - EJN5932 [pii]
AID - 10.1111/j.1460-9568.2007.05932.x [doi]
PST - ppublish
SO  - Eur J Neurosci. 2007 Dec;26(11):3229-36. doi: 10.1111/j.1460-9568.2007.05932.x. 
      Epub 2007 Nov 14.